Role of dopamine in Huntington's disease;À la recherche d'un rôle de la dopamine dans la maladie de Huntington

Medecine/Sciences

Volumn 22, Issue 2, 2006, Pages 115-117

  Caboche, Jocelyne ^a   Charvin, Delphine ^a  

^a Groupe Enzymologie Moléculaire et Fonctionnelle   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMINE; STRESS ACTIVATED PROTEIN KINASE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN;

AMINO ACID SEQUENCE; AUTOSOMAL DOMINANT INHERITANCE; GENE MUTATION; GENETIC CODE; HUNTINGTON CHOREA; NONHUMAN; NOTE; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL CULTURE; CHEMISTRY; CORPUS STRIATUM; CYTOLOGY; EXON; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; EXONS; HUMANS; HUNTINGTON DISEASE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, KNOCKOUT; MODELS, NEUROLOGICAL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OXIDATIVE STRESS; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 32644433021     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2006222115     Document Type: Note

References (13)

1. The Huntington's disease collaborative research group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
2. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
3. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537-48.
4. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-3.
5. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-10.
6. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-77.
7. Jakel RJ, Maragos WF. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci 2000; 23: 239-45.
8. Cyr M, Beaulieu JM, Laakso A, et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci USA 2003; 100: 11035-40.
9. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000; 15: 552-60.
10. Luo Y, Umegaki H, Wang X, et al. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 1998; 273: 3756-64.
11. Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988; 85: 5733-7.
12. Li H, Li SH, Yu ZX, et al. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci 2001; 21: 8473-81.
13. Charvin D, Vanhoutte P, Pages C, et al. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci USA 2005; 102: 12218-23.